The European Patent Office (EPO) has published patent application EP4522167A1, detailing "Novel psilocin prodrug compounds and methods of synthesizing the same." This publication, dated March 18, 2026, by Mydecine Innovations Group Inc., represents a new intellectual property filing in the pharmaceutical sector, specifically related to psilocin derivatives.

This patent filing does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in the research and commercialization of psilocin-based therapeutics. Companies operating in the pharmaceutical and drug development space, particularly those involved with psychedelic compounds, should be aware of this patent's existence as it may impact future research, development, and market exclusivity.